| ￥3000 | |
| Z05177-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 46.7 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 60-65 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized CLEC4A/DCIR hFc Chimera, Human, hFc Tag at 1 μg /ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-CLEC4A Antibody, hFc Tag with the EC50 of 29.8ng/ml determined by ELISA. »
The purity of CLEC4A/DCIR hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
CLEC4A/DCIR hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy. |
| Synonyms | CD367; Clec4a2; CLECSF6; DCIR; DDB27; HDCGC13P; LLIR; CLEC4A; DCIRLLIR |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
